

## Assessment of Biological and Anti-Cancer Activity, Design of Some Novel Heterocyclic Compounds, And Synthesis Based on Indole-Dione

1. Rana S. Al-Shemary

Received 2<sup>nd</sup> Oct 2023,  
Accepted 19<sup>th</sup> Oct 2023,  
Online 4<sup>th</sup> Nov 2023

<sup>1</sup> Dept. of Pharmaceutical Chemistry,  
College of Pharmacy, University of  
Babylon, Babylon, Iraq

**Abstract:** This search included synthesized new heterocyclic derivatives from Isatin (T) via reaction with 4-aminobenzoic acid to give (T2), and with SOCl<sub>2</sub> to give compound (T1), esterification to give (T3), reacted with hydrazine to give (T4) compound, and with anhydrides to give (T5,T6). The schiff base (T10) prepared from benzylaldehyde and (T9) prepared from (T2) and thiocarbohydrazide. (T8) compound synthesized from (T2) and semicarbazide by aring closer reaction in NaOH. This (T1-T10) compounds were measured biological and anticancer activity and give high good activity with (IC<sub>50</sub>=42.18,45.02 for compounds 12 and 3).

**Key words:** Isatin, Hydrazin, Thiocarbohydrazide, Anticancer activity, Semicarbazide.

### 1. Introduction

Indoles are heterocyclic compounds that have a large number of pathological applications, such as cancer, microbial and viral infections, depression, vomiting, and high blood pressure. They are also used in perfumes (1). One of its derivatives is indole-2,3-dione (Isatin). It contains tuberculosis-fighting qualities (2).

Isatin are important compounds in medicinal chemistry and possess a wide range of biological activities and chemical synthesis. For example, anti-cancer (3). Also, its derivatives, such as thiazolidinedione, are an important part of medicinal chemistry for developing anti-cancer treatments (4,5).

Heterocyclic Schiff bases are among the preferred compounds in the medical field and medicine. It is used in organic synthesis (6,7). Medical uses for Schiff's isatin bases include antioxidants (8), anti-coagulation (9), plasmodia (10), diabetes (11), HIV, anti-inflammatory and anti-cancer(12-15).

1,2,4-Triazoles compounds are widely involved with pharmacological activities such as antibacterial, Antifungal, anticarcinogenic and anticonvulsant properties(13-19).

In the study, acetin was reacted with triazole, Schiff's rules are for the purpose of giving results best as antimicrobials in low concentration

## 2. Materials and Method

### 2.1. General

A new compounds (T1-T10) were prepared via Isatin with (4-aminobenzoic acid in ethanol ,then with different anhydride to form imides compounds (Scheme 1).

Isatin and other chemicals were obtained from Fluka,CDH and BDH . Identified compounds by FTIR, <sup>1</sup>H and <sup>13</sup>C NMR, "Testseon Shimadzu (FT- IR 8400Series Japan)". <sup>1</sup>H NMR and <sup>13</sup>C NMR((Bruker,UltraShield 500 MHZ and 100 MHz).

#### 2.2.1. Synthesis of compound (T1)

➤ Isatin (0.02g, 0.065mol) was added to 4-aminobenzoic acid (0.0087 g, 0.065mol)

in 50 ml absolute ethanol, refluxed (10 hours), T.L.C (ethyl acetate :hexane 1:3) to reaction completed, then filtered , washed with water, recrystallized from ethanol (20) . The physical data in (Table 1).

The FT-IR spectrum(cm<sup>-1</sup>,vmax): compound [T1] Fig (1) and Table (1):

(3251-2999) OH acid , (3191) NH, ( 1616 ) C=N ,(1739) C=Oisatin. , (1688) C=O of carboxylic group. (1598) C=C ar. .

<sup>1</sup>HNMR (500MHz,DMSO-d<sub>6</sub>, ppm ) :12.9 (s,1H,OH), 10.9(s,1H,NH), 7.8-6.3) (m,8H,Ar-H).

<sup>13</sup>C NMR(DMSO-d<sub>6</sub>, ppm ): 112.12-155.01 (Ar-C), 155.55(C=N),163.69(C=O) , 167.43(COOH).

#### 2.2.2. Synthesis of compound (T2)

Compound (T1) (0.029.gm, 0.01.mol) in SOCl<sub>2</sub>(30.mL), refluxed ( 80°C for 2 hrs. , recrystallized from DCM (21). The physical data in (Table 1).

FT-IR(compound T2): 3212(NH),3070(CH ar.) ,1756(COCl),1577(C=N), 1421 (C=C), (1196) C-O, 1349(C-N),(646)C-Cl.

#### 2.2.3. Synthesis of Ester (T3)

Compound T2 (2.9 g, 0.01 mol), ethanol (15ml) ,H<sub>2</sub>SO<sub>4</sub> (5 drop), ref. (2-5)h. the yield extracted with chloroform after the solvent removed, dried anhydrous Na<sub>2</sub>SO<sub>4</sub> to give ester (1.90g) (22). (Table 1).

FTIR: 3015(CH ar.) ,2998(CH al.),1683(C=O),1132-1257) C-O, 1387(C-N).

<sup>1</sup>HNMR : 3.9(t,2H,CH<sub>2</sub>),1.9(d,3H,CH<sub>3</sub>),10.2 (s,1H-NH),6.5-7.9(m,8H,Ar-H.).

#### 2.2.4. Synthesis of Isatin Hydrazone (T4)

Ester (T3) (2.94 g, 0.01 mol) in THF (10 mL), hydrazine (1 mL, 0.12 mol) was added , 3-4h.ref. , (50 mL) water add to reaction , filtered, washed and recrystallized in ethanol. (23)(Table 1).

FTIR : 3053 (C-H ar.), 1736 (C=O), 3107 (NH), 3385 ( NH<sub>2</sub>), 1619 (C=N) ,1536(C=C),1142-1286)C-O , 1331(C-N).

<sup>1</sup>HNMR : 2.4(d,2H,NH<sub>2</sub>),10.6,8.4(s,1H-NH),6.5-7.9(m,8H,Ar-H.).

#### 2.2.5. Synthesis of compound (T5,T6)

(0.01mol,0.89g) of compound (T4) mixed with different anhydride , heated in oil bath at (180-185)<sup>0</sup>C for 30 minutes. The solid was cooled and recrystallized with ethanol (24) .(Table 1).

FTIR (compound T5): 3257 (NH), 3082(CH ar.), 1704 (C=O), 1623 (C=N), 1172-1200 (C-O), 1503 (C=C) , 1342( C-N).

<sup>1</sup>H NMR: δ 11.0 ,9.4 ( s,2H,NH), 6.9-7.6 (m,12H, Ar).

FTIR (compound T6): 3253 (NH), 3052 (CH ar.), 1736 (C=O), 1649 (C=N), 1175-1253 (C-O-C), 1618, 1459 (C=C), 1331 (C-N).

### 2.2.6. Synthesis of compound (T7)

Compound (T2) (0.01 mol) was added (1.82 g) of semicarbazide with 50 ml of sodium hydroxide solution (10%) mixed with stirring for 20 minutes, ice water added, (25) (Table 1).

FTIR: (3424, 3251) (NH<sub>2</sub>), 3191 (NH), (1700) (C=O), (3071) (CH<sub>ar.</sub>), 1622 (C=N), (1598-1505) (C=C), (1334) (C-N), (1163-1283) (C-O).

<sup>1</sup>H NMR: (6.3-7.8) (CH)<sub>ar.</sub>, (10.9, 9.9) (NH), (5.89) (NH<sub>2</sub>).

### 2.2.7. Synthesis of compound (T8)

A mixture of compound (T7), (0.01 mole, 0.473 gm) dissolved in (50 ml dioxane) and added sodium hydroxide 4% (0.01 mole,) was stirred (4h.), then added conc. HCl to acidified, the solid was recrystallized from absolute ethyl alcohol. (26)

FTIR of (T8): 3224 (OH), 1700 (C=O), 3070 (CH<sub>ar.</sub>), 1621 (C=N), 1602, 1582 (C=C), 1342 (C-N), (1125-1263) C-O,

<sup>1</sup>H NMR : 6.8-8.4 (CH<sub>ar.</sub>), 10.1 (OH), 10.78 (NH) .

<sup>13</sup>C NMR : (122.6-125.8) (CH<sub>ar.</sub>), 153.3 (C-OH), 166.8 (C=O), 138.8 (C=N).

### 2.2.8. Synthesis of compound (T9)

Compound (T2) (0.28g, 0.01 mol.) and thiocarbohydrazide (1.06g, 0.015 mol.), heat the mixture until it melts. Refrigerated product adding a solution of sodium bicarbonate to the equation Wash with water and filter. T.L.C to complete the reaction (hexane: ethyl acetate 1:2). Recrystallization of (ethanol) (27).

FTIR (compound T): 3448 (NH<sub>2</sub>), 3395 (NH), 1568 (C=N), 1655 (C=O), 1415 (C=Car.).

<sup>1</sup>H NMR: δ 13.01 (s, 1H, SH), 11.33 (s, 1H, NH), 7.62-6.54 (m, 8H, Ar-H), 5.87 (s, 2H, NH<sub>2</sub>) .

### 2.2.9. Synthesis of compounds (T10)

Compound (T9) (0.33 gm, 0.01 mol), (benzylaldehyde (0.35 mol), conc. H<sub>2</sub>SO<sub>4</sub> (2-3 drops) and ethanol (15 mL), 4-5h. ref. on a waterbath. Then cooled, filtered, washed (water), and recrystallized via ethanol. (28) (Table 1).


FTIR of compound T10 : 3424 (NH), 2933 (C-H al.), 3005 (C-H ar.), 1709 (C=O), 1577 (C=N), 1421 (C=C).

<sup>1</sup>H NMR: δ 10.74 (s, 1H, SH), 10.18 (s, 1H, NH), 8.47 (s, 1H, N=CH), 8.44-8.04 (m, 12H, Ar-H)..

**Table 1: Some of the physical properties of compounds (T1-T10)**

Com. NO.	Molecular Formula	M.Wt	Colour	m.p. °C	Yield %	Rf	(TLC)
T1	C <sub>15</sub> H <sub>10</sub> N <sub>2</sub> O <sub>3</sub>	266	Light yellow	280-282	81	0.69	ethyl acetate: n-hexane 1:3
T2	C <sub>15</sub> H <sub>9</sub> N <sub>2</sub> O <sub>2</sub> Cl	284	yellow	201-202	90	0.72	ethyl acetate: n-hexane 1:1
T3	C <sub>17</sub> H <sub>14</sub> N <sub>2</sub> O <sub>3</sub>	294	Orange	225-226	92	0.67	Acetone: n-hexane 1:2
T4	C <sub>15</sub> H <sub>12</sub> N <sub>4</sub> O <sub>2</sub>	280	White	251-252	88	0.75	Acetone:

			yellowish				n-hexane 1:1
<b>T5</b>	$C_{23}H_{14}N_4O_4$	410	Yellow	293-294	94	0.83	n-hexane: DCM 1:2
<b>T6</b>	$C_{19}H_{12}N_4O_4$	378	Orange	278-279	80	0.78	n-hexane: DCM 1: 1
<b>T7</b>	$C_{16}H_{13}N_5O_3$	323	Off - white	222-223	78	0.77	Acetone: n-hexane 1:2
<b>T8</b>	$C_{16}H_{11}N_5O_2$	305	Light brown	280-282	81	0.76	Benzene: acetone1:1
<b>T9</b>	$C_{16}H_{12}OS$	336	Orange -black	288-289	75	0.88	ethyl acetate: n-hexane 1:2
<b>T10</b>	$C_{24}H_{18}N_6OS$	438	brown	258-259	78	0.82	ethyl acetate: n-hexane 1:2



Scheme 1: Synthesis of Compounds (T1-T10)




Fig.1: FTIR of compound (T1)




Fig.2: <sup>1</sup>H NMR of compound (T1)




Fig.3: <sup>13</sup>CNMR of compound (T1)




Fig.4: FTIR of compound (T2)






Fig.7: FTIR of compound (T4)




Fig.8: <sup>1</sup>H NMR of compound (T4)




Fig.9: FTIR of compound (T5)




Fig.10: <sup>1</sup>H NMR of compound (T5)




Fig.11: FTIR of compound (T6)




Fig.12: FTIR of compound (T7)




Fig.13: <sup>1</sup>H NMR of compound (T7)




Fig.14: <sup>1</sup>H NMR of compound (T8)






Fig.17: FTIR Of compound (T10)




Fig.18: 1HNMR of compound (T10)


### 3. Biological productivity

The results showed that the compounds (T2,T3.T6,T7,T8,T9,T10) had high activity against *S. aureus* bacteria, low activity for (T5,T4).

the compounds(T5,T6,T7) had high activity against (E. coli) bacteria, low activity for (T2,T3,T8,T9,T10).

**Table 2: The biological activity of (T2-T10) compounds**

Comp. No.	E-coli(G-)	Staph. Aureus(G+)
Ciprofloxacin (Antibiotic) Standard	14	12
T2	9	16
T3	12	15
T4	10	11
T5	18	10
T6	15	13
T7	14	12
T8	10	12
T9	8	16
T10	12	15



**Fig. 19: Biological Effect of (T1-T10)compounds**

#### 4. Cytotoxic Action

The toxic effects of the prepared compounds(T5,T8,T9,T10) were evaluated using an MTT assay on a human breast cancer cell line (MCF7), it was show (T8 and T9) compounds had the most result with IC50 (25.03,28.73) comparing with control.

Table 3 :The anti-cancer activity of (T10) compound.

	concentration ( $\mu\text{g/ml}$ )	OD	OD	OD	average	% cell viability
	50	0.126	0.124	0.122	0.125	31.2604168
	40	0.145	0.146	0.152	0.151	35.34651682
	30	0.188	0.178	0.167	0.175	43.39267639
	20	0.277	0.234	0.286	0.266	55.45221792
	10	0.374	0.379	0.384	0.3723	69.04763322
	5	0.425	0.322	0.367	0.396	79.18725811
	2.5	0.428	0.34	0.378	0.38	89.38106579
	0	0.45	0.334	0.422	0.387	100
IC <sub>50</sub>	33.13 ( $\mu\text{g/ml}$ )					


Fig.20: Cytotoxic effect of T10, IC<sub>50</sub> = 33.13

Table 4: The anti-cancer activity of (T8) compound.

	concentration ( $\mu\text{g/ml}$ )	OD	OD	OD	average	% cell viability
	50	0.146	0.113	0.102	0.125	28.2604168
	40	0.125	0.143	0.132	0.121	32.45651680
	30	0.283	0.157	0.146	0.165	40.27267627
	20	0.177	0.284	0.186	0.166	46.4221732
	10	0.274	0.279	0.264	0.273	79.06763312
	5	0.305	0.352	0.337	0.336	82.25625809
	2.5	0.388	0.33	0.378	0.33	92.28106770
	0	0.44	0.414	0.352	0.397	100
IC <sub>50</sub>	25003 ( $\mu\text{g/ml}$ )					




Fig.21 : Cytotoxic effect of T8, IC<sub>50</sub> = 25.03

Table 5 :The anti-cancer activity of (T9) compound.

	concentration (µg/ml)	OD	OD	OD	average	% cell viability
	50	0.136	0.116	0.122	0.136	25.03328467
	40	0.115	0.144	0.135	0.131	28.90510949
	30	0.153	0.167	0.176	0.168	37.17435256
	20	0.277	0.284	0.296	0.266	63.4346181
	10	0.374	0.357	0.346	0.363	77.7431679
	5	0.375	0.382	0.387	0.386	82.81751825
	2.5	0.488	0.43	0.478	0.431	91.3634525
	0	0.34	0.44	0.452	0.497	100
IC <sub>50</sub>	27073 (µg/ml)					





Fig.22 : Cytotoxic effect of T9, IC<sub>50</sub> = 28.73.

Table 6 :The anti-cancer activity of (T5) compound.

	concentration ( $\mu\text{g/ml}$ )	OD	OD	OD	average	% cell viability
	50	0.236	0.2616	0.222	0.236	51.485394
	40	0.245	0.284	0.265	0.231	54.681383
	30	0.253	0.267	0.276	0.268	56.427670
	20	0.277	0.284	0.296	0.266	62.237438
	10	0.334	0.247	0.316	0.263	66.381338
	5	0.345	0.372	0.257	0.326	85.341630
	2.5	0.428	0.423	0.398	0.441	97.448245
	0	0.51	0.446	0.447	0.456	100
IC <sub>50</sub>	55.63 ( $\mu\text{g/ml}$ )					

Fig.23 : Cytotoxic effect of T5, IC<sub>50</sub> = 55.63

## 5. Conclusions

New heterocyclic compounds with Isatin. It has medicinal properties for drug development. Its synthesis and diagnosis.

The prepared compounds gave good results regarding antibacterial activity

## 6. References

1. Nalini, C., Silakari, O. (2018), Indoles: As Multitarget Directed Ligands in Medicinal Chemistry, Ch.8, Pages 285-321.
2. U. Usha Rani<sup>1</sup>, P. Sivappa Naidu<sup>1</sup>, G. Sukanya<sup>1</sup>, P. Sri Datha<sup>1</sup>, .Pramod Kumar, and, Venkata Rao Vutla (2017), Synthesis and Biological Evaluation of Isatin incorporated Quinoxalines as Anti-Tubercular Agents, Int. J. Pharm. Sci. Rev. Res., 47(2): 67-70.
3. J. Haribabu et al., Isatin based thiosemicarbazone derivatives as potential bioactive agents: Anti-oxidant and molecular docking studies, J. Mol. Struct.(2016) 1110, 15 April, Pages 185-195.

4. Varun et al. Isatin and its derivatives: a survey of recent syntheses, reactions, and applications, *Med. Chem. Comm.* (2019) 10(3): 351–368.
5. H. Kumar et al. (2019), Chemical Synthesis, Mechanism of Action and Anticancer Potential of Medicinally Important Thiazolidin-2,4-dione Derivatives, *Mini-Rev. Med. Chem.*, 19(18):1474-1516.
6. C.M. Da Silva et al., Schiff bases: A short review of their antimicrobial activities, *J. Adv. Res.* Volume 2, Issue 1, January 2011, Pages 1-8.
7. P. Przybylski, A. Huczynski, K. Pyta, B. Brzezinski, F. Bartl (2009), Biological properties of schiff bases and azo derivatives of phenols, *Curr Org Chem*, 13 (2), 124-148.
8. Andreani, A., Burnelli S., Granaiola M., Leoni A., and et al. (2010), New isatin derivatives with antioxidant activity, *European Journal of Medicinal Chemistry*, 45, Issue 4, April, Pages 1374-1378.
9. A. Ahmed et al. (2020), Docking studies, antitumor and antioxidant evaluation of newly synthesized porphyrin and metalloporphyrin derivatives, *Bioorganic Chemistry*. Volume 97, April, 103708.
10. Chiyanzu I., Clarkson C., Peter J. Smith, Lehman J., Gut J., Philip J. Rosenthal, Chibale K. (2005), Design, synthesis and anti-plasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives, *Bioorganic & Medicinal Chemistry*, Volume 13, Issue 9, 2 May, Pages 3249-3261.
11. A. Kumar et al. (2011), Exploration of antimicrobial and antioxidant potential of newly synthesized 2,3-disubstituted quinazoline-4(3H)-ones, *Bioorg. Med. Chem. Lett.* Volume 21, Issue 14, 15 July, Pages 4353-4357.
12. U. Usha Rani<sup>1</sup>, P. Sivappa Naidu<sup>1</sup>, G. Sukanya<sup>1</sup>, P. Sri Datha<sup>1</sup>, Pramod Kumar, and Venkata Rao Vutla (2017), Synthesis and Biological Evaluation of Isatin incorporated Quinoxalines as Anti-Tubercular Agents, *Int. J. Pharm. Sci. Rev. Res.*, 47(2): 67-70.
13. Prakash, CR; Raja, S; Saravanan, G (2010), Synthesis, Characterization and Anti-convulsant Activity of Novel Schiff Base of Isatin Derivatives, *Int. J. of Pharmacy and Pharmaceutical Sciences*, 2(4):177-181.
14. Panneerselvam, P; Kumar, NR; Murali, K (2010) Synthesis, Analgesic, Anti-inflammatory and Antimicrobial Activities of some Novel Schiff's Bases of -substituted Isatin, *Der Pharm. Chem.*, 2(1):28-37.
15. Chaluvvaraju, KC; Zaranappa, R (2011) Synthesis and Microbiological Evaluation of some Isatin Derivatives for Antimicrobial Properties, *Res. J. of Pharmaceutical, Biological and Chemical Sciences*, 2(1):541.
16. B. Kahveci and A.A. Ikizler, (2000) Study of some 4,5-dihydro-1,2,4-triazole -5-one derivatives, *Acta Pol. Pharm. Drug Res.*, 57(2), 119-122.
17. N. Aggarwal, R. Kumar, P. Dureja, J.M. Khurana, (2011), Synthesis, antimicrobial evaluation and QSAR analysis of novel nalidixic acid based 1,2,4-triazole derivatives, *Eur. J. Med. Chem.*, 46(9), 4089-4099.
18. M. Shalini, P. Yogeewari, D. Sriram, J.P. Stables, (2009), Cyclization of the semicarbazone template of aryl semicarbazones: synthesis and anticonvulsant activity of 4,5-diphenyl-2H-1,2,4-triazol-3(4H)-one. *Biomed. & pharm.*, 63(3), 187-193.

19. A.T. Mavrova, D. Wesselinova, Y.A. Tsenov, P. Denkova ,(2009) Synthesis, cytotoxicity and effects of some 1,2,4-triazole and 1,3,4-thiadiazol derivatives on immunocompetent cells, Eur. J. Med.Chem. 44(1), 63-69.
20. Hassan A. A., Shawky A. M., and Shehatta H. S., (2011). Chemistry and heterocyclization of thiosemicarbazones. J. of Heterocyclic Chemistry, 49(1): 21–37.
21. Gaina V, Gaina C. (2007),Bismaleimides and Biscitraconimides with Bisallyl Groups, High Perform Polym.;19(2):160-174.
22. Aggarwal, N.; Kumar, K.; Dureja, P.; Khurana, J.M. Synthesis of novel nalidixic acid-based 1,3,4-thiadiazole and 1,3,4-oxadiazole derivatives as potent antibacterial agents. Chem. Biol. Drug Des., 2012, 79, 384-397.
23. Rana N., Nagham M. Aljamali , J. Majid. (2014). Synthesis, Identification of Heterocyclic Compounds and Study of Biological Activity. Asian Journal. Research Chemistry, 7(7) 664-676.
24. J.Mirek , M. Adamczyk , E. Chojnacka-Wojcik and A.Naparzewska,pol.J. Pharmacol.Pharm.30,685-693 (1978).
25. Katritzky, A. R., Yoshioka-Tarver, M., El-Gendy, B. E. D. M., & Hall, C. D. (2011). Synthesis and photochemistry of pH-sensitive GFP chromophore analogues. Tetrahedron Letters, 52(17), 2224-2227.
26. Hussain A. K. Sharba , Rida H.Al-Bayati ,Nadjet Rezki & Mohammed R. Aouad, . (2005).Synthesis of Thiadiazoles & 1,2,4-Triazoles Derived from Cyclopropane Dicarboxylic Acid, Molecules 10,1155-1156.
27. Gupta A. K., Prachand, S., Patel, A., and Jain, S. (2012). Synthesis of some 4-Amino-5-(substituted-phenyl)-4H-[1, 2, 4] triazole-3-thiol derivatives and Antifungal activity. Int. J. of Pharm. and Life Sci.,1857-1848, (3)7.
28. Zahraa Salim M. Al-Garawi, Ivan Hameed R. Tomi, and Ali Hussein R. Al-Daraji(2012), Synthesis and Characterization of New Amino Acid-Schiff Bases and Studies their Effects on the Activity of ACP, PAP and NPA Enzymes (In Vitro); Journal of Chemistry, 9(2), 962-969.